Adma Biologics (ADMA) Change in Account Payables (2016 - 2025)
Historic Change in Account Payables for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$4.9 million.
- Adma Biologics' Change in Account Payables fell 40135.97% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 6291.81%. This contributed to the annual value of $4.1 million for FY2024, which is 810.11% up from last year.
- Latest data reveals that Adma Biologics reported Change in Account Payables of -$4.9 million as of Q3 2025, which was down 40135.97% from $9.3 million recorded in Q2 2025.
- In the past 5 years, Adma Biologics' Change in Account Payables ranged from a high of $13.8 million in Q3 2022 and a low of -$12.0 million during Q4 2022
- Its 5-year average for Change in Account Payables is $772526.3, with a median of $142000.0 in 2025.
- In the last 5 years, Adma Biologics' Change in Account Payables soared by 1628000.0% in 2024 and then tumbled by 40135.97% in 2025.
- Quarter analysis of 5 years shows Adma Biologics' Change in Account Payables stood at -$4.9 million in 2021, then crashed by 146.61% to -$12.0 million in 2022, then skyrocketed by 141.73% to $5.0 million in 2023, then dropped by 21.07% to $3.9 million in 2024, then plummeted by 223.69% to -$4.9 million in 2025.
- Its Change in Account Payables was -$4.9 million in Q3 2025, compared to $9.3 million in Q2 2025 and $142000.0 in Q1 2025.